16:24 EDT Caris Life Sciences (CAI) still sees 2026 revenue $1.0B-$1.02B, consensus $1.01B
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAI:
- Caris Life Sciences’ ChromoSeq receives MolDX approval
- Caris Life Sciences initiated with a Buy at Jefferies
- Caris Life Sciences initiated with a Neutral at Piper Sandler
- Caris Life Sciences price target lowered to $30 from $34 at Evercore ISI
- Caris Life Sciences launches Caris ChromoSeq tumor profiling assay